JP2019521160A - Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド - Google Patents

Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド Download PDF

Info

Publication number
JP2019521160A
JP2019521160A JP2019502239A JP2019502239A JP2019521160A JP 2019521160 A JP2019521160 A JP 2019521160A JP 2019502239 A JP2019502239 A JP 2019502239A JP 2019502239 A JP2019502239 A JP 2019502239A JP 2019521160 A JP2019521160 A JP 2019521160A
Authority
JP
Japan
Prior art keywords
subject
disease
mna
pharmaceutically acceptable
crp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521160A5 (https=
Inventor
パルカ，コンラッド
ゲビクキ，ジェルツィ
ウィチョールコウスカ，マルツエナ
エー． セファリ，ヨージニオ
エー． セファリ，ヨージニオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmena SA
Original Assignee
Pharmena SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmena SA filed Critical Pharmena SA
Publication of JP2019521160A publication Critical patent/JP2019521160A/ja
Publication of JP2019521160A5 publication Critical patent/JP2019521160A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019502239A 2016-07-18 2017-07-16 Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド Pending JP2019521160A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363712P 2016-07-18 2016-07-18
US62/363,712 2016-07-18
PCT/IB2017/054293 WO2018015861A1 (en) 2016-07-18 2017-07-16 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein

Publications (2)

Publication Number Publication Date
JP2019521160A true JP2019521160A (ja) 2019-07-25
JP2019521160A5 JP2019521160A5 (https=) 2020-08-13

Family

ID=59399457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019502239A Pending JP2019521160A (ja) 2016-07-18 2017-07-16 Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド

Country Status (12)

Country Link
US (1) US20190282560A1 (https=)
EP (1) EP3484475B1 (https=)
JP (1) JP2019521160A (https=)
CN (1) CN109562108A (https=)
AU (1) AU2017298648B2 (https=)
DK (1) DK3484475T3 (https=)
ES (1) ES2967074T3 (https=)
FI (1) FI3484475T3 (https=)
MX (1) MX389845B (https=)
PL (1) PL3484475T3 (https=)
RU (1) RU2744615C2 (https=)
WO (1) WO2018015861A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540771A (ja) * 2020-09-04 2023-09-26 上海医薬集団股▲分▼有限公司 炎症性腸疾患を治療する方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN112294786A (zh) * 2019-08-01 2021-02-02 深圳大学 一种含乙胺丁醇与他汀类药物的抗结核组合药物
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
EP4213821A2 (en) * 2020-09-21 2023-07-26 The Regents of the University of California Immunological effects of metabolites

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525058A (ja) * 1997-04-02 2001-12-04 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アテローム性動脈硬化疾患に関する個人の危険性プロフィールを確認する手段
JP2007517833A (ja) * 2004-01-12 2007-07-05 ファルメナ エスピー ゼット オー．オー． 四級ピリジニウム塩の血管保護剤としての使用
JP2009500445A (ja) * 2005-07-11 2009-01-08 フアルメナ・ノース・アメリカ・インコーポレーテツド スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
WO2009047291A2 (en) * 2007-10-12 2009-04-16 Politechnika Lódzka Use of quaternary pyridinium salts for inhibiting cancer metastases
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT131118B (de) 1929-04-19 1933-01-10 Ig Farbenindustrie Ag Verfahren zur Darstellung von N-Methylpyridiniumchlorid.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3614408A (en) 1969-02-20 1971-10-19 British Petroleum Co Waveform analyzing system, particularly for chromatographs, wherein the waveform is integrated between selected peaks and valleys
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4115390A (en) 1977-08-19 1978-09-19 Nardi John C Method for the preparation of 1-alkyl pyridinium chlorides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
CA2629913A1 (en) * 2005-12-09 2007-06-14 Cerecon Ag Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
DK2026651T3 (da) * 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
WO2009137527A1 (en) * 2008-05-06 2009-11-12 Cortria Corporation 1-methylnicotinamide analogs
PL226999B1 (pl) * 2013-06-11 2017-10-31 Univ Jagiellonski Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525058A (ja) * 1997-04-02 2001-12-04 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アテローム性動脈硬化疾患に関する個人の危険性プロフィールを確認する手段
JP2007517833A (ja) * 2004-01-12 2007-07-05 ファルメナ エスピー ゼット オー．オー． 四級ピリジニウム塩の血管保護剤としての使用
JP2009500445A (ja) * 2005-07-11 2009-01-08 フアルメナ・ノース・アメリカ・インコーポレーテツド スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
WO2009047291A2 (en) * 2007-10-12 2009-04-16 Politechnika Lódzka Use of quaternary pyridinium salts for inhibiting cancer metastases
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. Vol.105, Issue 24, JPN6021021382, 2013, pages 1871 - 1880, ISSN: 0004524477 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540771A (ja) * 2020-09-04 2023-09-26 上海医薬集団股▲分▼有限公司 炎症性腸疾患を治療する方法
JP7564342B2 (ja) 2020-09-04 2024-10-08 上海医薬集団股▲分▼有限公司 炎症性腸疾患を治療する方法

Also Published As

Publication number Publication date
PL3484475T3 (pl) 2024-03-11
FI3484475T3 (fi) 2023-12-12
MX389845B (es) 2025-03-20
ES2967074T3 (es) 2024-04-25
RU2019104343A3 (https=) 2020-09-17
MX2019000721A (es) 2019-06-10
US20190282560A1 (en) 2019-09-19
RU2019104343A (ru) 2020-08-18
AU2017298648B2 (en) 2023-05-11
CA3030805A1 (en) 2018-01-25
DK3484475T3 (da) 2023-11-27
AU2017298648A1 (en) 2019-01-31
EP3484475B1 (en) 2023-09-27
WO2018015861A1 (en) 2018-01-25
EP3484475A1 (en) 2019-05-22
RU2744615C2 (ru) 2021-03-11
CN109562108A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US11034674B2 (en) Methods of treating inflammation or neuropathic pain
CN105228453B (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
JP2019521160A (ja) Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド
US20140066469A1 (en) Treatment of diseases associated with inflammation
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
KR20200013644A (ko) 간세포 암종의 치료
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
US20240293369A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CA3030805C (en) 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
TW202110432A (zh) 包含１５—ＨＥＰＥ及／或１５—ＨＥＴｒＥ之組合物及治療或預防心血管代謝疾病、代謝症候群及／或相關疾病之方法
US20250114363A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high serum uric acid level
US12600715B2 (en) Soluble guanylate cyclate activators for treating systemic sclerosis
HK40061449A (en) Methods of treating inflammation or neuropathic pain
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療
TW202400145A (zh) 治療ｓ１ｐ受體相關病況之方法
CN120435291A (zh) 用于多发性硬化的治疗性酪氨酸激酶抑制剂
EA050266B1 (ru) Фармацевтическая композиция, включающая 1-(3-циано-1-изопропилиндол-5-ил)пиразол-4-карбоновую кислоту
Nobili et al. β-Adrenoceptor Antagonists and Antianginal Drugs
SULLIVAN Colon Cancer Risk Rises With Low Vitamin D
Bag et al. Role of Primary Care Provider in the Referral and Care of Thoracic Organ Transplant Patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012